AMTX vs SMID

AMTX exhibits weak financial health with a Piotroski F-Score of 4/9, indicating a fragile operational foundation. The absence of an Altman Z-Score and negative profitability metrics—especially a -38.96% profit margin and -8.96% ROA—signal severe operational distress. Despite a 14.2% YoY revenue growth and recent positive EPS surprises, the company remains unprofitable with negative cash flow and extreme liquidity issues (current ratio of 0.07). The stock trades at a price/sales of 0.77, but this is misleading given the lack of sustainable earnings and deteriorating balance sheet. The 52-week price range of $1.22–$3.66 reflects high volatility and speculative risk.

Smith-Midland exhibits a stable financial profile with a Piotroski F-Score of 4/9 and an exceptionally clean balance sheet (Debt/Equity 0.08). While the current price of $33.98 trades at a premium to the Graham Number ($23.31), it remains significantly below the growth-based intrinsic value of $69.62. The company is delivering high-alpha returns with an ROE of 26.04% and explosive earnings growth of 52.60% YoY. Despite bearish technicals and minimal insider sentiment, the fundamental valuation relative to sector peers (P/E 14.40 vs Sector 45.20) suggests a strong value opportunity.